Overview

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2031-08-01

Target enrollment:

Participant gender:

Summary

This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).

Phase:

PHASE2

Details

Lead Sponsor:

SUNHOChinaBioPharmaceutical CO., Ltd.

Collaborator:

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

Treatments:

Injections
Topotecan